KR101828934B1 - 양극성 장애의 치료방법 - Google Patents

양극성 장애의 치료방법 Download PDF

Info

Publication number
KR101828934B1
KR101828934B1 KR1020127032128A KR20127032128A KR101828934B1 KR 101828934 B1 KR101828934 B1 KR 101828934B1 KR 1020127032128 A KR1020127032128 A KR 1020127032128A KR 20127032128 A KR20127032128 A KR 20127032128A KR 101828934 B1 KR101828934 B1 KR 101828934B1
Authority
KR
South Korea
Prior art keywords
delete delete
enantiomer
formula
compound
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127032128A
Other languages
English (en)
Korean (ko)
Other versions
KR20130112706A (ko
Inventor
성 제임스 리
스잔 마리에 멜닉
Original Assignee
에스케이바이오팜 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이바이오팜 주식회사 filed Critical 에스케이바이오팜 주식회사
Publication of KR20130112706A publication Critical patent/KR20130112706A/ko
Application granted granted Critical
Publication of KR101828934B1 publication Critical patent/KR101828934B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020127032128A 2010-06-30 2011-06-27 양극성 장애의 치료방법 Active KR101828934B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/827,505 US9610274B2 (en) 2010-06-30 2010-06-30 Methods for treating bipolar disorder
US12/827,505 2010-06-30
PCT/KR2011/004676 WO2012002687A2 (en) 2010-06-30 2011-06-27 Methods for treating bipolar disorder

Publications (2)

Publication Number Publication Date
KR20130112706A KR20130112706A (ko) 2013-10-14
KR101828934B1 true KR101828934B1 (ko) 2018-03-29

Family

ID=45400168

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127032128A Active KR101828934B1 (ko) 2010-06-30 2011-06-27 양극성 장애의 치료방법

Country Status (13)

Country Link
US (2) US9610274B2 (https=)
EP (1) EP2590645B1 (https=)
JP (1) JP5881692B2 (https=)
KR (1) KR101828934B1 (https=)
CN (1) CN102985085B (https=)
AU (1) AU2011272156B2 (https=)
BR (1) BR112012033738A2 (https=)
CA (1) CA2801241C (https=)
ES (1) ES2654615T3 (https=)
MX (2) MX2012014686A (https=)
PL (1) PL2590645T3 (https=)
RU (1) RU2653408C2 (https=)
WO (1) WO2012002687A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2435403T3 (es) 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
KR102173587B1 (ko) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US9359290B2 (en) 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
KR102309836B1 (ko) 2013-07-18 2021-10-12 에스케이바이오팜 주식회사 비만의 치료
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
ES2970887T3 (es) 2016-09-06 2024-05-31 Axsome Malta Ltd Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP4316592A3 (en) 2016-10-06 2024-05-01 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds and uses thereof
KR102635938B1 (ko) * 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
KR102643275B1 (ko) 2017-07-31 2024-03-04 재즈 파마슈티칼즈 아일랜드 리미티드 카바모일 페닐알라니놀 유사체 및 이의 용도
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR20260033050A (ko) 2023-06-29 2026-03-10 액섬 테라퓨틱스, 인크. 수유 여성에게 솔리암페톨을 투여하는 방법
WO2025165760A1 (en) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996007637A1 (en) 1994-09-09 1996-03-14 Yukong Limited Novel phenylalkylaminoalcohol carbamates and process for preparing the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260667A (en) 1993-06-10 1997-05-26 Lilly Co Eli Preventing emesis or treating sexual dysfunction using tetrahydrobenz[cd]indole 6-carboxamides
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
EP0873308B1 (en) 1996-10-10 2002-01-02 SK Corporation O-carbamoyl-phenylalaninol compounds and their pharmaceutically useful salts
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
WO1999055674A1 (en) 1998-04-28 1999-11-04 Dainippon Pharmaceutical Co., Ltd. 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
US20010029262A1 (en) 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
US20010034320A1 (en) 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
WO2002050071A1 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
WO2002067922A1 (en) 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in the treatment of pain
CN1262272C (zh) 2001-02-27 2006-07-05 奥索-麦克尼尔药品公司 用于预防或治疗运动障碍的氨基甲酸酯化合物
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
JP2004537526A (ja) 2001-06-12 2004-12-16 メルク　エンド　カムパニー　インコーポレーテッド 片頭痛の治療又は予防用ｎｒ２ｂ受容体拮抗薬
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
JP2006502180A (ja) 2002-09-20 2006-01-19 ファイザー株式会社 ５−ｈｔ４レセプターモジュレーターとしてのｎ−置換されたピペリジニル−イミダゾピリジン化合物
BRPI0409592A (pt) 2003-04-21 2006-05-02 Pfizer compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3
UA86204C2 (uk) 2003-09-03 2009-04-10 Пфайзер Инк. Сполуки бензімідазолону, які мають 5-нт4 рецепторну агоністичну активність
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
CA2587481A1 (en) * 2004-10-28 2006-05-11 Sk Corporation Phenylalkylamino carbamates adjunctive therapy for depression
GEP20105053B (en) 2005-04-08 2010-07-26 Pfizer Prod Inc Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
ES2435403T3 (es) * 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
ES2344469T3 (es) 2005-06-22 2010-08-27 Sk Holdings Co., Ltd. Tratamiento de disfuncion sexual.
AU2005335241B9 (en) 2005-07-26 2012-12-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating substance-related disorders
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
CA2673487A1 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica Nv Phenylalkylamino carbamate compositions
HUP0700370A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
KR102173587B1 (ko) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101097605B1 (ko) 2009-11-04 2011-12-22 알.에프 에이치아이씨 주식회사 도허티 증폭기
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996007637A1 (en) 1994-09-09 1996-03-14 Yukong Limited Novel phenylalkylaminoalcohol carbamates and process for preparing the same
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법

Also Published As

Publication number Publication date
US9610274B2 (en) 2017-04-04
AU2011272156B2 (en) 2015-02-12
EP2590645A2 (en) 2013-05-15
EP2590645A4 (en) 2014-01-22
AU2011272156A1 (en) 2013-02-07
US20120004300A1 (en) 2012-01-05
JP5881692B2 (ja) 2016-03-09
MX360030B (es) 2018-10-19
KR20130112706A (ko) 2013-10-14
US9907777B2 (en) 2018-03-06
CN102985085B (zh) 2018-10-02
US20170151209A1 (en) 2017-06-01
WO2012002687A2 (en) 2012-01-05
RU2653408C2 (ru) 2018-05-08
BR112012033738A2 (pt) 2017-08-08
JP2013533253A (ja) 2013-08-22
CA2801241A1 (en) 2012-01-05
EP2590645B1 (en) 2017-10-04
WO2012002687A3 (en) 2012-04-26
RU2012155118A (ru) 2014-08-10
PL2590645T3 (pl) 2018-03-30
ES2654615T3 (es) 2018-02-14
CA2801241C (en) 2018-07-17
MX2012014686A (es) 2013-02-11
CN102985085A (zh) 2013-03-20

Similar Documents

Publication Publication Date Title
KR101828934B1 (ko) 양극성 장애의 치료방법
KR101785072B1 (ko) 하지 불안 증후군의 치료방법
US20260055054A1 (en) Methods for treating attention-deficit/hyperactivity disorder
KR101783633B1 (ko) 섬유근육통 증후군의 치료 방법
KR20150139522A (ko) 탈력발작의 치료
CN101217949A (zh) 治疗睡眠-清醒病症
CA2587481A1 (en) Phenylalkylamino carbamates adjunctive therapy for depression
HK1178796B (en) Methods of treating restless legs syndrome

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9